Date |
Title |
Download |
|
Vion Receives Response from FDA on Special Protocol Assessment for Onrigin™ |
|
|
Vion Issues Management Statement Regarding Trading Volume of Company’s Common Stock |
|
|
Vion Announces Filing of Special Protocol Assessment for Onrigin™ |
|
|
Vion Announces FDA Conclusion • HOVON Trial As Designed Does Not Gain SPA Agreement |
|
|
Vion Files for Chapter 11 Bankruptcy • Company to Continue Efforts to Complete Special Protocol Assessment and Sell its Assets |
|
|
Vion Receives Complete Response Letter for Onrigin™ from the U.S. Food and Drug Administration |
|
|
Vion Reports 2009 Third Quarter Results • Quarterly Conference Call |
|
|
Vion Engages Merriman Curhan Ford to Evaluate Strategic Alternatives |
|
|
Vion to Present at Rodman & Renshaw Healthcare Conference |
|
|
Vion Announces Results of the Oncologic Drugs Advisory Committee Meeting for Onrigin™ |
|
|
Vion Reports 2009 Second Quarter and Six-Month Results |
|
|
Vion Announces Oncologic Drugs Advisory Committee Meeting for Onrigin™ |
|
|
Vion Presents Data on Onrigin™ Elderly AML Trials at the ASCO® Annual Meeting |
|
|
Vion to Present Data on Onrigin™ at the ASCO® Annual Meeting |
|
|
Vion Reports 2009 First Quarter Results • Quarterly Conference Call |
|
|
Vion's Receives a Standard Review from the FDA for its New Drug Application for Onrigin™ |
|
|
Vion's New Drug Application for Onrigin™ Accepted for Review by the FDA |
|
|
Vion Reports 2008 Full-Year and Fourth-Quarter Results |
|
|
Vion Submits New Drug Application for Onrigin™ |
|
|
Vion Presents Additional Survival Data on Onrigin™ (Laromustine) Injection at ASH Annual Meeting |
|
|
Vion to Present Survival Data on Laromustine at ASH Annual Meeting |
|
|
Vion Adds Tanya Lewis to Senior Management Team |
|
|
Vion Updates Conference Call Information |
|
|
Vion Reports 2008 Second Quarter and Six-Month Results • Quarterly Conference Call to be Held Thursday November 6 at 8:30 a.m. |
|
|
Vion Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine® in Combination with Induction Therapy in Poor Prognosis AML Patients |
|
|
Vion Enters into Agreement with HOVON to Conduct a Phase III Clinical Trial of Cloretazine® in combination with Frontline AML and MDS Therapy |
|
|
Vion is Delisted from Nasdaq Stock Market |
|
|
Vion Reports 2008 Second Quarter and Six-Month Results • Quarterly Conference Call to be Held Thursday August 7 at 8:30 a.m. |
|
|
Vion Announces Presentation of Data of Cloretazine® (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting |
|
6.2.08 |
Vion Announces Presentation of Interim Data from
Pivotal Phase II Trial of Cloretazine® (VNP40101M) in Acute
Myelogenous Leukemia at the ASCO® Annual Meeting |
|
6.2.08 |
Vion Announces Presentation of Data from Phase III Trial of Cloretazine® (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO® Annual Meeting |
|
5.30.08 |
Vion To Present Clinical Data on Cloretazine®
(VNP40101M) at the ASCO® Annual Meeting |
|
5.8.08 |
Vion Announces Initiation of Clinical Trial of Cloretazine® (VNP40101M) in Combination with Cytarabine |
|
5.8.08 |
Vion To Appeal Nasdaq Delisting |
|
5.6.08 |
Vion to Host Conference Call To Discuss 2008 First Quarter Financial Results |
|
5.5.08 |
Vion Reports 2008 First Quarter Results |
|
4.15.08 |
Vion Files Plan With Nasdaq |
|
3.26.08 |
Vion Receives Nasdaq Notice |
|
3.17.08 |
Vion Reports 2007 Fourth Quarter and Year-End Results |
|
3.14.08 |
Vion to Host Conference Call To Discuss 2007 Fourth Quarter and Year-End Financial Results |
|
3.7.08 |
Vion Regains NASDAQ Listing Compliance |
|
2.20.08 |
Vion to Implement a One-for-Ten
Reverse Stock Split |
|
2.15.08 |
Vion Pays Interest on
7.75% Convertible Senior Notes |
|
2.13.08 |
Vion Holds Special Meeting
of Stockholders |
|
2.4.08 |
Vion Adds William Hahne,
M.D. to Senior Management Team |
|
1.8.08 |
Vion Announces FDA Lift
of Clinical Hold on Phase III Study of Cloretazine® (VNP40101M)
and Cytarabine in Relapsed AML |
|
We hope we have provided you with answers to some of your questions. If you have a specific question please contact us.
